Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

Sponsor
University of Miami
Study ID
NCT03022565
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

  • Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorinostat — DRUG
    Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.

Study Details

This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.

Key Dates

First listed
Jan 16, 2017
Start date
Jan 31, 2020
Status verified
Feb 2020
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vorinostat
    Vorinostat: * 400 mg orally, once daily for 15 days.

Primary Outcome Measure

Degree of transformation from a class 2 phenotype into a cell phenotype that resembles normal melanocytes. [ Time Frame: From Baseline to 15 Days of Protocol Therapy, Up to 4 Weeks ]

Related Studies